Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
News and analysis

Canada‚s only Di Bella cancer clinic a very lonely place

David Helwig
CMAJ October 17, 2000 163 (8) 1030;
David Helwig
London, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

One year after Canada‚s first Di Bella method (DBM) cancer clinic opened in Toronto‚s Italian district, the number of patients it has attracted can be counted on 2 hands. In fact, 1 hand might do the trick.

”I must say, it is a little discouraging at times,” said Dr. Aaron Malkin, 12 months after setting up the Isola Bella Oncological Multiple Therapy Clinic in a second-floor office in August 1999. During its first year the clinic received many inquiries, Malkin said in an interview, but it actually treated only ”5 to 10” patients. This was a far cry from the situation in 1997 and 1998, when the ”cure” developed by Italian physiologist Luigi Di Bella was attracting a firestorm of international attention. As Charlotte Gray reported in CMAJ in 1998 (158[11]:1510-2), the phones of Toronto MP Joe Volpe were then ringing 10 times a day with inquiries about DBM. Most callers wanted Volpe, an Italian-Canadian who was then parliamentary secretary to the health minister, to explain why the ”miracle” cocktail was not available in Canada.

Di Bella‚s controversial cocktail combines bromocriptine, melatonin and somatostatin or octreotide with complementary substances, including vitamin C and shark cartilage; it is taken with low doses of chemotherapeutic agents such as cyclophosphamide.

Under immense political and popular pressure, Italian health officials supported historical studies of DBM patients and 11 uncontrolled phase II trials. The historical review, reported last year in Cancer (86[10]:2143-9), concluded that the 5-year survival rate for DBM patients was significantly lower than for patients receiving conventional therapy, with no evidence of improved survival prospects. The phase II trials, reported in the BMJ (1999;318:224-8), found insufficient efficacy to warrant further clinical trials.

Malkin thinks his Toronto clinic is the only one of its type in North America. The clinic‚s original advertising was limited to the Buffalo News and a Toronto-based Italian-language newspaper, but in August he began promoting the clinic and DBM on a Web site, www.oncomtc.com.

Three doctors are involved in the clinic. Malkin, an internist with a doctorate in biochemistry, was head of clinical biochemistry at Toronto‚s Sunnybrook Hospital from 1961 to 1992. The other physicians are DBM specialists based in Italy. Malkin meets initially with the patient, then consults with his Italian colleagues, who develop a treatment protocol that is prepared by an Italian pharmacy. Initial treatment lasts at least 3 months. ”For all of these services, the Isola Bella Clinic will require a retainer of $3800 for the first month and $1300 for each month thereafter,” Malkin‚s Web site advises.

The site acknowledges that evidence of DBM‚s efficacy is ”anecdotal” and there is ”currently no acceptable Canadian medical proof that this treatment will cure cancer.”

Why, then, did he bother introducing the widely discredited protocol here? ”I‚m curious about the results, and I‚m looking after the patient‚s interest,” he said. ”All of the information until now has been anecdotal. Di Bella and his colleagues didn‚t do a careful study.”

Because some components of DBM have known anticancer properties, Malkin ”thought it would be interesting to see what happened” during treatment. As for his own lack of patients, he says: ”I‚m not worried about that. I‚m semi-retired. I‚m doing other things.”

At the Canadian Cancer Society, medical affairs director Dr. Barbara Whylie was unwilling to express direct criticism of the Di Bella treatment. Whylie said the society recognizes the growing public interest in complementary cancer therapies and supports the right of patients to make their own decisions about treatment. However, ”before abandoning conventional therapies and taking up any complementary therapy, they should thoroughly discuss implications with their physician or health care provider.” —

PreviousNext
Back to top

In this issue

CMAJ
Vol. 163, Issue 8
17 Oct 2000
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Canada‚s only Di Bella cancer clinic a very lonely place
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Canada‚s only Di Bella cancer clinic a very lonely place
David Helwig
CMAJ Oct 2000, 163 (8) 1030;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Canada‚s only Di Bella cancer clinic a very lonely place
David Helwig
CMAJ Oct 2000, 163 (8) 1030;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Will Canada follow US lead on RU 486?
  • Gene mutation may explain multiple-birth pregnancies
  • Greening of health care goal of new coalition
Show more News and Analysis

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire